Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost-Utility Analysis.
Budesonide orodispersible tablets
Cost-effective
Cost–utility
Economic evaluation
Eosinophilic esophagitis
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
26
08
2021
accepted:
08
10
2021
pubmed:
27
10
2021
medline:
12
11
2021
entrez:
26
10
2021
Statut:
ppublish
Résumé
Budesonide orodispersible tablets (BOT) have been approved in Europe and Canada for the treatment of eosinophilic esophagitis (EoE), a rare and chronic disease. The objective of this study was to assess the economic impact of BOT on both the induction and maintenance of clinico-pathological remission of EoE by performing a cost-utility analysis (CUA). For both the induction and maintenance settings, BOT was compared to no treatment in a target population of adult patients with EoE non-responsive to proton pump inhibitor (PPI) treatment. Markov models were developed for the induction and maintenance settings over 52-week and life-time horizons, respectively. Analyses were performed from both a Canadian Ministry of Health (MoH) and societal perspective. The resulting incremental cost-utility ratios (ICURs) were compared to a willingness-to-pay (WTP) threshold of $50,000 Canadian dollars/quality-adjusted life-year (QALY). Sensitivity and scenario analyses were conducted to assess the robustness of the base-case results. In the base-case probabilistic analysis, BOT compared to no treatment resulted in an ICUR of $1073/QALY and $30,555/QALY from a MoH perspective in the induction and maintenance settings, respectively. BOT was a cost-effective option for both induction and maintenance in > 99% of Monte Carlo simulations. In the scenario analyses, the deterministic ICUR of BOT compared to no treatment varied from $682/QALY to $8510/QALY in the induction setting and $21,005/QALY to $55,157/QALY in the maintenance setting. BOT was cost-effective compared to no treatment for both the induction and maintenance of clinico-pathological remission of EoE in patients non-responsive to PPIs.
Identifiants
pubmed: 34699003
doi: 10.1007/s12325-021-01957-7
pii: 10.1007/s12325-021-01957-7
doi:
Substances chimiques
Tablets
0
Budesonide
51333-22-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
5737-5751Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Straumann A, Katzka DA. Diagnosis and treatment of eosinophilic esophagitis. Gastroenterology. 2018;154(2):346–59.
doi: 10.1053/j.gastro.2017.05.066
Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155(4):1022–33 e10.
doi: 10.1053/j.gastro.2018.07.009
Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128(1):3–20 e6 (quiz 1–2).
doi: 10.1016/j.jaci.2011.02.040
Navarro P, Arias A, Arias-Gonzalez L, Laserna-Mendieta EJ, Ruiz-Ponce M, Lucendo AJ. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2019;49(9):1116–25.
doi: 10.1111/apt.15231
Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154(2):319–32 e3.
doi: 10.1053/j.gastro.2017.06.067
Syed AA, Andrews CN, Shaffer E, Urbanski SJ, Beck P, Storr M. The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study. Aliment Pharmacol Ther. 2012;36(10):950–8.
doi: 10.1111/apt.12053
Stewart MJ, Shaffer E, Urbanski SJ, Beck PL, Storr MA. The association between celiac disease and eosinophilic esophagitis in children and adults. BMC Gastroenterol. 2013;30(13):96.
doi: 10.1186/1471-230X-13-96
American Gastroenterological Association. Treatment of eosinophilic esophagitis (EoE): clinical decision support tool. Gastroenterology. 2020;158(6):1787.
doi: 10.1053/j.gastro.2020.03.070
Rank MA, Sharaf RN, Furuta GT, Aceves SS, Greenhawt M, Spergel JM, et al. Technical review on the management of eosinophilic esophagitis: a report from the AGA Institute and the Joint Task Force on allergy-immunology practice parameters. Gastroenterology. 2020;158(6):1789–810 e15.
doi: 10.1053/j.gastro.2020.02.039
Eluri S, Runge TM, Hansen J, Kochar B, Reed CC, Robey BS, et al. Diminishing effectiveness of long-term maintenance topical steroid therapy in PPI non-responsive eosinophilic esophagitis. Clin Transl Gastroenterol. 2017;8(6):e97.
doi: 10.1038/ctg.2017.27
Greuter T, Safroneeva E, Bussmann C, Biedermann L, Vavricka SR, Katzka DA, et al. Maintenance treatment of eosinophilic esophagitis with swallowed topical steroids alters disease course over a 5-year follow-up period in adult patients. Clin Gastroenterol Hepatol. 2019;17(3):419–28 e6.
doi: 10.1016/j.cgh.2018.05.045
Greuter T, Bussmann C, Safroneeva E, Schoepfer AM, Biedermann L, Vavricka SR, et al. Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a therapeutic concept. Am J Gastroenterol. 2017;112(10):1527–35.
doi: 10.1038/ajg.2017.202
Straumann A, Conus S, Degen L, Frei C, Bussmann C, Beglinger C, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2011;9(5):400–9.e1.
doi: 10.1016/j.cgh.2011.01.017
Gonsalves N, Yang GY, Doerfler B, Ritz S, Ditto AM, Hirano I. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology. 2012;142(7):1451–9 e1 (quiz e14–5).
doi: 10.1053/j.gastro.2012.03.001
Arias A, Gonzalez-Cervera J, Tenias JM, Lucendo AJ. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146(7):1639–48.
doi: 10.1053/j.gastro.2014.02.006
Lucendo AJ. Meta-analysis-based guidance for dietary management in eosinophilic esophagitis. Curr Gastroenterol Rep. 2015;17(10):464.
doi: 10.1007/s11894-015-0464-y
Lucendo AJ, Arias A, Gonzalez-Cervera J, Yague-Compadre JL, Guagnozzi D, Angueira T, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol. 2013;131(3):797–804.
doi: 10.1016/j.jaci.2012.12.664
AVIR Pharma Inc. Product monograph including patient medication information: JORVEZA™ (Budesonide Orodisperisble Tablets 1 mg) 2019.
Dr. Falk Pharma UK Ltd. Jorveza, INN-budesonide—European Medicines Agency—summary of product characteristics. 2018 [cited 2020]. Available from: https://www.ema.europa.eu/en/documents/product-information/jorveza-epar-product-information_en.pdf .
Greuter T, Hirano I, Dellon ES. Emerging therapies for eosinophilic esophagitis. J Allergy Clin Immunol. 2020;145(1):38–45.
doi: 10.1016/j.jaci.2019.10.027
Lucendo AJ, Miehlke S, Schlag C, Vieth M, von Arnim U, Molina-Infante J, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74–86 e15.
doi: 10.1053/j.gastro.2019.03.025
Miehlke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Bajbouj M, et al. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut. 2016;65(3):390–9.
doi: 10.1136/gutjnl-2014-308815
Straumann A, Lucendo AJ, Miehlke S, Vieth M, Schlag C, Biedermann L, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020.
Dellon ES. Cost-effective care in eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2019;123(2):166–72.
doi: 10.1016/j.anai.2019.04.010
Asher Wolf W, Huang KZ, Durban R, Iqbal ZJ, Robey BS, Khalid FJ, et al. The six-food elimination diet for eosinophilic esophagitis increases grocery shopping cost and complexity. Dysphagia. 2016;31(6):765–70.
doi: 10.1007/s00455-016-9739-1
Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol. 2015;110(5):626–32.
doi: 10.1038/ajg.2014.316
Statistics Canada. Life tables, Canada, Provinces and Territories, 1980/1982 to 2016/2018. 2020 [cited 2020]. Available from: https://www150.statcan.gc.ca/n1/en/catalogue/84-537-X2019002 .
Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, et al. Rapid recurrence of eosinophilic esophagitis activity after successful treatment in the observation phase of a randomized, double-blind, double-dummy trial. Clin Gastroenterol Hepatol. 2019.
Kartman B, Gatz G, Johannesson M. Health state utilities in gastroesophageal reflux disease patients with heartburn: a study in Germany and Sweden. Med Decis Mak. 2004;24(1):40–52.
doi: 10.1177/027298X03261563
Alberta PROMS and EQ5D Research and Support Unit. Alberta population norms for EQ-5D-5L. 2018. Available from: https://apersu.ca/about-eq-5d/norms/ .
Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak. 2006;26(4):410–20.
doi: 10.1177/0272989X06290495
Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada, 4th edn. 2017. Available from: Available from: https://www.cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition
Hiremath G, Kodroff E, Strobel MJ, Scott M, Book W, Reidy C, et al. Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care. Clin Res Hepatol Gastroenterol. 2018;42(5):483–93.
doi: 10.1016/j.clinre.2018.03.003
Cotton CC, Erim D, Eluri S, Palmer SH, Green DJ, Wolf WA, et al. Cost utility analysis of topical steroids compared with dietary elimination for treatment of eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15(6):841–9 e1.
doi: 10.1016/j.cgh.2016.11.032
de Heer J, Miehlke S, Rosch T, Morgner A, Werner Y, Ehlken H, et al. Histologic and clinical effects of different topical corticosteroids for eosinophilic esophagitis: lessons from an updated meta-analysis of placebo-controlled randomized trials. Digestion. 2020;1:1–9.
Rokkas T, Niv Y, Malfertheiner P. A network meta-analysis of randomized controlled trials on the treatment of eosinophilic esophagitis in adults and children. J Clin Gastroenterol. 2020.
Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adher. 2012;6:39–48.
doi: 10.2147/PPA.S24752
Hirano I, Furuta GT. Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis. Gastroenterology. 2020;158(4):840–51.
doi: 10.1053/j.gastro.2019.09.052
Lucendo AJ, Molina-Infante J, Arias A, von Arnim U, Bredenoord AJ, Bussmann C, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5(3):335–58.
doi: 10.1177/2050640616689525
Matza LS, Kim KJ, Yu H, Belden KA, Chen AF, Kurd M, et al. Health state utilities associated with post-surgical Staphylococcus aureus infections. Eur J Health Econ. 2019;20(6):819–27.
doi: 10.1007/s10198-019-01036-3
Bongers ML, de Ruysscher D, Oberije C, Lambin P, Uyl-de Groot CA, Belderbos J, et al. Model-based cost-effectiveness of conventional and innovative chemo-radiation in lung cancer. Int J Technol Assess Health Care. 2017;33(6):681–90.
doi: 10.1017/S0266462317000939
Stal JM, Gregor JC, Preiksaitis HG, Reynolds RP. A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture. Can J Gastroenterol. 1998;12(1):43–9.
doi: 10.1155/1998/947087
Arias-Gonzalez L, Rey-Iborra E, Ruiz-Ponce M, Laserna-Mendieta EJ, Arias A, Lucendo AJ. Esophageal perforation in eosinophilic esophagitis: a systematic review on clinical presentation, management and outcomes. Dig Liver Dis. 2019.
Government of Ontario. Ontario schedule of benefits: physician services under the Health Insurance Act (September 6, 2019 (effective October 1, 2019)) 2019.
Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38(2):161–89.
doi: 10.1086/380796
Ontario Ministry of Health and Long-Term Care. Ontario case costing analysis tool. 2019 [cited 2019 September]. Available from: https://stage.hsim.health.gov.on.ca/hdbportal/ .
Statistics Canada. Table 18-10-0004-13 Consumer Price Index by product group, monthly, not seasonnaly adjusted. 2021 February 2021 [cited 2021 February]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1810000413&pickMembers%5B0%5D=1.2&cubeTimeFrame.startMonth=01&cubeTimeFrame.startYear=2018&referencePeriods=20180101%2C20180101 .
Statistics Canada. Table 14-10-0320-02 Average usual hours and wages by selected characteristics, monthly, unadjusted for seasonality. 2021.